Home / Market News / $HAE
fiscal.ai Corporate Catalyst Impact 65/100 ● positive

Barrington Research Adjusts Haemonetics Price Target to $145

Nov 6, 2026, 7:07 PM UTC · Primary ticker $HAE

Barrington Research increased its price target for Haemonetics Corporation to $145 from $140, while maintaining an Outperform rating. This adjustment follows Haemonetics' strong fiscal Q2 earnings, where revenue surpassed analyst expectations, indicating positive financial performance.

Barrington Research's decision to raise Haemonetics' price target to $145 from $140, alongside maintaining an Outperform rating, is a direct response to the company's robust fiscal second-quarter earnings. Haemonetics reported revenue of $357.8 million, significantly exceeding the FactSet consensus estimate of $345.1 million. This positive financial performance suggests strong operational execution and market demand for Haemonetics' products. For traders, this indicates a potential short-term positive sentiment boost for HAE stock, as analyst upgrades often lead to increased investor confidence. The long-term implication is that the company's growth trajectory appears solid, potentially attracting more institutional investors. A key opportunity for traders lies in the potential for continued upward momentum if future earnings reports maintain this positive trend.

$HAE positive Price target increase after strong earnings
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.